Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones Continue reading →

NEW YORK--(BUSINESS WIRE)--Today, Target ALS launched the first-ever comprehensive effort to discover ALS biomarkers The Target ALS Diagnosis Initiative through which the organization will invest $15 million in collaborative grantmaking and the development of new scientific resources. The initiative was developed in response to input from over 100 scientists, patients, caregivers and other thought leaders. Continue reading →

SAN DIEGO, Dec. 14, 2020 /PRNewswire/ --Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, today announced a $100 million Series B financing. Continue reading →

NUTLEY, N.J. Continue reading →

New science, innovations, and guidelines surrounding resuscitation strategies for sudden cardiac arrest (SCA) develop at a rapid pace, and the Citizen CPR Foundation (CCPRF) is dedicated to ensuring lay rescuers and the healthcare community are kept up to date. CCPRF was founded in 1987 with a vision to strengthen the Chain of Survival following sudden cardiac arrest by educating lay rescuers, dispatchers, EMTs and paramedics, emergency department personnel, and specialists in intensive care units. The foundations biennial Emergency Cardiovascular Care Update (ECCU) Conference transformed into the Cardiac Arrest Survival Summit and this year to simply the Citizen CPR Foundation Virtual Summit, which was held Dec Continue reading →

Israeli cell therapy specialist Neurogenesis Ltd., said new phase II data has shown that treatment with its autologous cell therapy candidate NG-01 in progressive multiple sclerosis (MS) patients led to an 80% to 90% reduction in disease progression at 12 months compared to a pretreatment period and a 90% reduction in relapses compared to placebo-treated patients. The results are highly significant in all parameters and show much more efficacy than any other treatment in progressive MS, Dimitrios Karussis, lead principal investigator and director of the MS Center at Hadassah Medical Center in Jerusalem, told BioWorld. Karussis explained that there are currently very effective medications for stopping relapses and slowing the progression of relapsing remitting MS, but not very successful ones for progressive disease. Continue reading →

The Telegraph Israel announced on Saturday that it is establishing full diplomatic relations with the relatively isolated Himalayan kingdom of Bhutan, the latest in a string of international deals designed to show Israels growing acceptance abroad. The circle of recognition of Israel is widening, said Israeli foreign minister, Gabi Ashkenazi. Continue reading →